5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%

被引：0
|
作者：
Gadgeel, S. [1 ]
Rodriguez-Abreu, D. [2 ]
Halmos, B. [3 ]
Garassino, M. C. [4 ,5 ]
Kurata, T. [6 ]
Cheng, Y. [7 ]
Jensen, E. [8 ]
Shamoun, M. [8 ]
Rajagopalan, K. [8 ]
Paz-Ares, L. [9 ,10 ]
机构：
[1] Henry Ford Hlth, Dept Internal Med, Henry Ford Canc Inst, Detroit, MI USA
[2] Univ Los Palmas de Gran Canaria, CHU Insular Materno Infant Gran Canaria, Las Palmas Gran Canaria, Spain
[3] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY USA
[4] Univ Chicago Med & Biol Sci, Thorac Oncol Program, Chicago, IL USA
[5] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[6] Kansai Med Univ Hosp, Dept Thorac Oncol, Osaka, Japan
[7] Jilin Canc Hosp, Dept Oncol, Changchun, Jilin, Peoples R China
[8] Merck Co Inc, Rahway, NJ USA
[9] Univ Complutense Madrid, Univ 12 Octubre, H12OCNIO Lung Canc Unit, Madrid, Spain
[10] Ciberonc, Madrid, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
pembrolizumab; NSCLC; PD-L1-negative;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA14.05
引用
收藏
页码：S77 / S78
页数：2
相关论文
共 50 条
  • [41] Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
    Lopes, Gilberto
    Wu, Yi-Long
    Kudaba, Iveta
    Kowalski, Dariusz
    Cho, Byoung Chul
    Castro, Gilberto
    Srimuninnimit, Vichien
    Bondarenko, Igor
    Kubota, Kaoru
    Lubiniecki, Gregory M.
    Zhang, Jin
    Kush, Debra A.
    Mok, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
  • [42] The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%
    Toyota, Y.
    Hata, T.
    Yamada, T.
    Goto, Y.
    Kijima, T.
    Watanabe, S.
    Furuya, N.
    Oba, T.
    Ikoma, T.
    Nakao, A.
    Tanimura, K.
    Taniguchi, H.
    Yoshimura, A.
    Fukui, T.
    Murata, D.
    Kaira, K.
    Shiotsu, S.
    Hibino, M.
    Okada, A.
    Takayama, K.
    ANNALS OF ONCOLOGY, 2024, 35
  • [43] Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
    Marmarelis, M. E.
    Mathew, D.
    Bauml, J. M.
    Hwang, W. -T.
    Zhang, J.
    Singh, A.
    D'Avella, C.
    Davis, C.
    Ye, D.
    Sun, L.
    Ciunci, C.
    Zhang, N.
    Aggarwal, C.
    Cohen, R. B.
    Minn, A. J.
    Wherry, E. J.
    Langer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S122 - S123
  • [44] ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy
    Zou, Wei
    Yaung, Stephanie J.
    Fuhlbrueck, Frederike
    Ballinger, Marcus
    Peters, Eric
    Palma, John F.
    Shames, David S.
    Gandara, David
    Jiang, Yuqiu
    Patil, Namrata S.
    JCO PRECISION ONCOLOGY, 2021, 5 : 827 - 838
  • [45] 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1-Positive Advanced NSCLC
    Herbst, R.
    Garon, E.
    Kim, D.
    Cho, B. C.
    Gervais, R.
    Perez-Gracia, J. L.
    Han, J.
    Majem, M.
    Forster, M. D.
    Monnet, I.
    Novello, S.
    Gubens, M. A.
    Boyer, M.
    Su, W.
    Samkari, A.
    Jensen, E. H.
    Piperdi, B.
    Baas, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S223 - S224
  • [46] Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy
    Hellmann, Matthew D.
    Janne, Pasi A.
    Opyrchal, Mateusz
    Hafez, Navid
    Raez, Luis E.
    Gabrilovich, Dmitry, I
    Wang, Fang
    Trepel, Jane B.
    Lee, Min-Jung
    Yuno, Akira
    Lee, Sunmin
    Brouwer, Susan
    Sankoh, Serap
    Wang, Lei
    Tamang, David
    Schmidt, Emmett, V
    Meyers, Michael L.
    Ramalingam, Suresh S.
    Shum, Elaine
    Ordentlich, Peter
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 1019 - 1028
  • [47] PD-L1 Overexpression in NSCLC Inversely Correlated with Survival of NSCLC Patients
    Zhong, Hua
    Zhou, Yan
    Han, Baohui
    Liu, Xianxun
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S669 - S669
  • [48] PD-L1 Expression is Related to Tumor Staging in NSCLC
    Wang, Hangjun
    Agulnik, Jason
    Kasymjanova, Goulnar
    Wang, Anna Y.
    Cohen, Victor
    Small, David
    Pepe, Carmela
    Sakr, Lama
    Fiset, Pierre O.
    Auger, Manon
    Camilleri-Broet, Sophie
    Alameldin, Mona
    Chong, George
    van Kempen, Leon
    Spatz, Alan
    MODERN PATHOLOGY, 2018, 31 : 755 - 755
  • [49] PD-L1 Expression is Related to Tumor Staging in NSCLC
    Wang, Hangjun
    Agulnik, Jason
    Kasymjanova, Goulnar
    Wang, Anna Y.
    Cohen, Victor
    Small, David
    Pepe, Carmela
    Sakr, Lama
    Fiset, Pierre O.
    Auger, Manon
    Camilleri-Broet, Sophie
    Alameldin, Mona
    Chong, George
    van Kempen, Leon
    Spatz, Alan
    LABORATORY INVESTIGATION, 2018, 98 : 755 - 755
  • [50] Distribution of PD-L1 Tumor Expression by Assay Type in Patients with Metastatic NSCLC (MNSCLC)
    Velcheti, V.
    Cao, X.
    Liu, F.
    Patwardhan, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1779 - S1780
12345